• KU Leuven researchers discover how to break the negative feedback loop to improve cancer immunotherapy

    Tuesday January 16th 2024

  • Sequana Medical granted US CPT® III reimbursement codes for alfapump® system

    Wednesday January 3rd 2024

  • Orionis Biosciences announces first patient dosed in Phase 1 clinical trial of ORB-011 in patients with advanced solid tumors

    Wednesday November 15th 2023

  • SwiftPharma and PlantForm target blockbuster cancer drug with new contract manufacturing agreement for plant-made biosimilars

    Tuesday November 14th 2023

  • Belgian researchers demonstrate that the gut microbiome can help predict the course of multiple sclerosis

    Thursday October 26th 2023

  • Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission

    Thursday October 19th 2023

  • SwiftPharma launches ODIN.AI: A groundbreaking AI-augmented antibody discovery platform

    Monday October 9th 2023

  • Triple discovery unveils insights into type 2 diabetes

    Thursday September 28th 2023

  • Your news here?

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV

    Friday September 8th 2023

  • SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure

    Friday September 1st 2023

Strategic Partners